The Bioflux®, their flagship product, is the first application built around these components where they have tailored their IoT hardware, RTOS and cloud for the diagnostic cardiac market. It is a single-unit mobile cardiac telemetry (MCT) device that demonstrates high-precision and transmission of ambulatory patients’ ECG information. Al-Siddiq further explains, “It is a complete solution for remote cardiac monitoring that merges seamlessly with physicians’ existing platforms and workflows. Unlike most of our competitors, we have a global platform, three channels of ECG, and complete arrhythmia detection.” As a four-in-one monitoring solution and the only one of its kind in the market, Bioflux® offers MCT, Event, Holter, and extended Holter studies. It is a compact and easily adaptable device with a quick emergency response.
The Bioflux® technology has been long approved by the FDA and is quite popular among doctors all across the country. Al-Siddiq mentions enthusiastically, “Just recently, our Bioflux® was able to detect new-onset atrial fibrillation in a patient, and our team contacted the patient straightaway and had her go to a hospital for immediate care. This is a great example of how real-time remote patient monitoring can catch emergent and high-risk health complications and set the patient on the path to preventative care.”
The company is planning to extend this technology to the consumer market. At present, Biotricity is working on developing their “Biocentrix” solution, a personal heart monitor for people who are at risk for cardiovascular disease, or who are already struggling with some sort of heart issue. Unlike lifestyle wearables, Biocentrix will provide consumers with the same clinical information regarding their heart’s performance that their doctor uses. Biotricity is also expanding into other preventative healthcare markets. Al-Siddiq explains, “We’re planning to leverage our proprietary remote patient monitoring platform for various industries, and plans are underway to pipeline new solutions across a spectrum of health applications, including remote COPD monitoring, fetal monitoring, sleep apnea monitoring, and other chronic conditions. We received ethics approval to investigate mobile wireless fetal monitoring in 2017, and in March of this year (2019), our University of Calgary-based R&D program commenced collecting clinical data for both our fetal/maternal and ambulatory adult heart rate variability (HRV) monitoring systems.”